Trump Executive Order Ignites Psychedelics Stock Surge, Compass Pathways CEO to Address Market

A surprise executive order from President Donald Trump has sent shockwaves through the nascent psychedelic medicine sector, triggering a massive rally in related stocks. The directive, aimed at expediting research and access, prompted immediate double-digit share price surges for key players, with Compass Pathways leading the charge with a staggering 53% intraday spike. The move signals a significant and sudden shift in the federal regulatory landscape for psychedelic therapies.

The order specifically targets the FDA's review process, mandating the issuance of expedited review vouchers for psychedelics that have received a 'breakthrough' designation. This could slash review times from six-to-ten months down to just one or two. This provision directly benefits several front-running companies, including Compass Pathways, AtaiBeckley, and Definium Therapeutics, all of which have therapies holding that coveted breakthrough status. The market's explosive reaction reflects the immense financial and developmental pressure this policy change places on the regulatory timeline.

The immediate fallout is a repricing of the entire sector, with the AdvisorShares Psychedelics ETF (PSIL) soaring to its highest level in nearly a year. The surge places intense scrutiny on the business models and clinical pipelines of these firms, as accelerated pathways to market could reshape competitive dynamics overnight. Compass Pathways CEO Kabir Nath is set to discuss the implications, highlighting the high-stakes environment where regulatory decisions now translate directly into volatile, multi-billion dollar market movements.